Ovarian Cancer Palliative Care May Decrease Readmission Rates, Expert Says

Video

The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.

Patients with ovarian cancer who received palliative care had a decreased risk of being readmitted at the 90-day time point, according to Alex Francoeur, MD.

In a conversation with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, Francoeur, a resident at The University of California, Los Angeles, detailed overall readmissions and how palliative care helped to reduce index hospitalization cost, the findings of which were noted as being significant.

The study was conducted using the National Readmissions Database, which allowed investigators to track each patient over the course of a year to determine how many times they were readmitted. The study noted that those who were referred to palliative care most likely had multiple comorbidities.

Transcript:

We used a large national database called the NRD—the National Readmissions Database—to answer the question [of readmission rates for patients with ovarian cancer]. What we found when we looked at women who had an in-patient palliative care consultation during admission for ovarian cancer, the rate of readmission dramatically decreased from about a [41%] readmission [to about] 27%, which correlated to an odds ratio of about 0.59 which, was quite a significant drop. This was looking at the 90-day readmission rate.

We also looked at a couple of other factors such as the number of readmissions with this database; you can track an individual patient over a calendar year and see how many times they were readmitted. We found that there was a decrease in the overall number of readmissions, as well, by about 50%. When we looked at the overall cost, there was a decrease in the cost of the index hospitalization of almost $2000. Both of those findings were significant as well.

Reference

Francoeur A, Chervu NL, Mardock AL, et al. Access to palliative care and association with readmission rates in patients with ovarian cancer. Presented at: 2023 Annual Meeting on Women’s Cancer; March 25-28; Tampa, Florida.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content